Miniaturisation and design-for-manufacture of a fibre-optic pressure and flow sensor for guiding minimally invasive cardiovascular therapies

点击翻译按钮获取中文摘要

Echopoint Medical are a new med-tech start-up who are focused on developing new technology to significantly improve diagnosis and treatment of cardiovascular disease (CHD).Globally, cardiovascular disease is the leading cause of death among women and men (1.8M patients in the UK). Many of these patients have narrowings or blockages of blood vessels in their heart that limit blood flow, which can lead to chronic pain (angina) and heart attacks. One of the most common treatments is to use a wire mesh tube, known as a "stent", to hold the diseased vessel open and restore adequate blood flow to the heart muscle. During the implantation of these stents, clinicians' treatment decisions are often guided by data from medical devices placed inside the arteries of the heart. However, today's devices provide only incomplete information about disease in the heart and consequently many patients are incompletely or incorrectly treated. Women with cardiovascular disease are underserved: compared with men, they present with a higher burden of symptoms and experience similar or worse outcomes, but are less likely to have obstructions that can be treated by stents.Echopoint will address a key need: to provide concurrent pressure and flow measurements from inside coronary arteries to significantly improve diagnosis and treatment for patients with cardiovascular disease -- particularly those with obstructive coronary artery disease and coronary microvascular dysfunction. The applicants have developed new technology that uses miniature fibre optic sensors to measure both blood pressure and flow from inside arteries. These sensors will provide key clinical data to improve clinical decision making about whether to place a stent in the vessel and also to guide treatments for patients who do not receive stents.Funding from this project will be transformative and enable Echopoint Medical to offer a cost-effective product for the NHS. Our current sensor has been shown to be highly accurate; however, we face two key challenges: 1) a size reduction to permit integration into devices called guidewires that are used in current clinical practice and 2) a significant reduction in manufacturing costs. For the first, we will perform the key step of reducing the sensor from two optical fibres to a single optical fibre: a challenging but attainable with close links to the University College London. For the second, we will work closely with manufacturing subcontractors in the UK to ensure scale-up with significant cost reductions for competing effectively in global markets.